Tests in Alzheimer's disease mouse models have shown that hydrogen sulphide can improve cognitive and motor function by 50 percent.
List view / Grid view
Alzheimer's disease (AD)
Filter the results
According to researchers, the more small tau protein variants expressed by neurons, the slower neurofibrillary tangles form.
The field of oncology has successfully applied precision medicine approaches to diagnosis and treatment. Success has been driven by a growing understanding of the underlying biology of cancer; the emergence of innovative tools and technologies for biomarker identification and detection; and considerable advocacy by patients, physicians and policymakers that has…
In this article Maria Bernabeu, Group Leader at EMBL, Barcelona, discusses why it is important to research and develop novel therapeutics for cerebral malaria and how her research group intends to develop a 3D blood-brain barrier model for this purpose.
Researchers have shown that 70 percent of Alzheimer’s patients have high levels of proteins associated with dysfunction in the endosomal trafficking system in their spinal fluid.
Researchers used integrative network biology analysis to identify the molecular mechanisms that may drive Alzheimer’s and identified a potential therapeutic intervention.
A team fused the peptide somatostatin to a brain transport protein and found it treated memory loss associated with Alzheimer's in mice.
Scientists who developed the E22W42 DC vaccine suggest it could be safer and more effective than previous anti-amyloid Alzheimer’s therapies.
Hannah Balfour explores how genetic variation in G-protein-coupled receptors (GPCRs) and the proteins that regulate the duration of G protein signalling could be contributing to disease and people’s divergent responses to the same therapeutics.
New findings suggest that late-onset Alzheimer's Disease (AD) is driven by epigenetic changes in the brain.
Scientists have produced the first pathoconnectome - an open access map for other researchers that shows how eye disease can alter retinal circuitry.
Researchers have developed a molecule that can restore lost connections in the spinal cords and brains of mice with cerebellar ataxia, Alzheimer's disease and spinal cord injury.
Although many potential targets have been identified for Alzheimer’s disease (AD), there is no effective treatment for this debilitating condition. In this article, Monika Schmidt and Sheraz Gul delve into the key proteins implicated in AD and suggest how phenotypic assays could aid in AD drug discovery.